What is this?
cGMP release testing applies verified compendial methods or validated custom methods to drug substances, drug products, tablets, capsules, excipients, and other materials to support batch disposition and CoA issuance.
Connect release testing to a defensible batch decision
Use validated or verified methods to support batch disposition, Certificate of Analysis (CoA) issuance, stability programs, and regulatory documentation.
For cGMP work, the testing plan must connect each specification and quality attribute to an appropriate method, representative sample, approved procedure, calculation, review pathway, and reporting requirement. Triclinic Labs coordinates method development, validation or verification, method transfer, release testing, CoA support, stability testing, and investigation documentation as one controlled workflow. Our scientists evaluate atypical and out-of-specification results in context rather than treating each instrument run as an isolated activity.
Content scientifically reviewed by Andy Gilkison, Ph.D., Senior Director, Method Development at Triclinic Labs · Updated 9/1/2026
Overview of cGMP Release Testing Services
When is it used?
Use release testing when a lot must be dispositioned for clinical supply, commercial supply, stability, incoming material qualification, investigation closure, or regulatory submission support.
What are limitations?
Release testing depends on a suitable method with the validation, verification, or transfer evidence required for its intended use. The method, specification, reference standards, sample plan, system suitability, deviations, OOS handling, and CoA wording must be aligned before testing.
What sample amounts are needed?
Amounts depend on the test panel, monograph, destructive tests, replicate needs, retains, and retesting policy. Enough material must be provided for the planned specification and any confirmed repeats.
Complementary Techniques
Complementary techniques are selected around each release specification and may include X-ray powder diffraction (XRPD), Raman and Fourier-transform infrared (FTIR) spectroscopy, nuclear magnetic resonance (NMR), chromatography, mass spectrometry, thermal analysis, Karl Fischer titration, particle-size analysis, microscopy, elemental analysis, and compendial tests.
What does FDA care about?
FDA cares about method status, data integrity, sample traceability, standards, calculations, analyst review, deviation/OOS handling, CoA accuracy, and lifecycle control.
What are common mistakes?
Common mistakes include using exploratory data as release evidence, validating the wrong matrix, ignoring sample preparation, under-documenting controls, relying on one technique when orthogonal evidence is needed, or failing to define the decision before testing.
What is Triclinic's experience with this technique
Triclinic supports real-world cGMP release testing by coordinating controlled analytical methods, documentation, review, and reporting around the quality decision the data must support. Applications include API, excipient, raw-material, intermediate, and finished-material testing; stability pulls; method transfer or verification; CoA support; and investigations when release data, specifications, or material history require analytical interpretation.
Regulatory framework, controlled execution, and reporting
Release testing must be planned and documented for the decision it supports. The testing package may need to address laboratory controls under 21 CFR 211.160, testing and release requirements under 21 CFR 211.165, and complete laboratory records under 21 CFR 211.194, together with the applicable specification, method status, quality agreement, and internal procedures.
| Control area | Release-testing expectation | Typical evidence |
|---|---|---|
| Method readiness | The procedure must be validated, verified, or transferred as appropriate for the material, matrix, specification, and laboratory. | Approved procedure, validation or verification report, transfer conclusion, and system suitability |
| Controlled execution | Representative samples, qualified standards, calculations, instruments, analysts, and deviations must be traceable. | Controlled worksheets, raw data, audit trail, sample records, calculations, and review documentation |
| Result assessment | Out-of-specification (OOS) and atypical results require evaluation under the applicable quality process. | Documented laboratory assessment, investigation support, impact assessment, and approved conclusion |
| Reporting | The report or Certificate of Analysis must reflect the approved specification and state only what the data support. | Reviewed result table, method references, specification comparison, deviations, and authorized report or CoA |
Triclinic supplies analytical results and scientific interpretation within the agreed scope. The client’s authorized quality unit makes the final batch-disposition decision unless a governing quality agreement assigns a different authorized process.
What changes when the work is cGMP?
Exploratory data can help choose a method, but release or filing-support data require controlled execution. The method must be suitable for the matrix, the quality attribute must be defined, reference standards and controls must be appropriate, and the report or CoA must say only what the data support.
| cGMP concern | Why it matters | Practical control |
|---|---|---|
| Method status | Exploratory, verified compendial, validated custom, and transferred methods have different evidence requirements. | Define status before testing and document any development, verification, validation, or transfer work. |
| Sample matrix | Specificity can fail in real drug product, excipient, talc, low-dose, or complex solid mixtures. | Use representative material, placebo/matrix controls, spike studies, or orthogonal methods where needed. |
| Data integrity | Release or stability results must survive QA review, audit, and regulatory scrutiny. | Use controlled records, system suitability, analyst review, deviations/OOS process, and traceable calculations. |
Specific instruments and capabilities for cGMP Release Testing Services
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this cGMP service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| Karl Fischer water determination | Mettler Toledo V20 and C20 systems | Volumetric and coulometric KF water-content analysis for solids, liquids, and formulations. |
| Particle-size analysis | Malvern Mastersizer 3000 v.3.70 with Malvern Access Configurator v.2.20 | Dry and wet PSD method development, validation, transfer, verification, and release-testing support. |
| X-ray powder diffraction | Rigaku SmartLab diffractometers with Cu source; 1D capability; reflection and transmission geometries; D/teX Ultra 250 detector | Phase identification, quantitative phase analysis, crystallinity, solid-form control, and cGMP XRPD method support. |
| Infrared and FT-Raman spectroscopy | Thermo Nicolet iS50 with OMNIC v9.11 software | Identification, spectral comparison, functional-group analysis, and controlled release-support methods. |
| Nuclear magnetic resonance spectroscopy | Bruker 400 MHz UltraShield Avance AVII with TopSpin 3.2 | Identity, purity, quantitative NMR, reference-material verification, and release-support testing. |
| Thermogravimetric analysis | TA Instruments Q50 and TA Discovery 5500 TGA systems | Mass loss, moisture or volatile content, decomposition, residue, and cGMP thermal-method support. |
| Differential scanning calorimetry | TA Instruments Q2000 and Q2500 Discovery DSC systems | Melting, crystallization, glass transition, heat capacity, compatibility, transition enthalpy, and modulated DSC support. |
cGMP Method Readiness Before Batch Release Testing
This example uses release testing as a readiness decision rather than only a lab execution step. A cGMP release-testing program may involve CoA issuance, finished-product and bulk-lot testing, reference standard qualification, method development, method validation, method transfer, detection-limit testing, linearity, precision, repeatability, accuracy, and quantitation-limit testing. The point of the case is to confirm method status before the sample is treated as a batch-release submission.
| Release-readiness question | Why it matters |
|---|---|
| Is the method exploratory, verified, validated, or transferred? | The method status determines whether the result can support release, stability, filing support, or investigation closure. |
| Are standards, controls, and sample matrix appropriate? | System suitability and specificity must be defensible for the actual product or material being tested. |
| Are acceptance criteria and report language defined? | A CoA or release report should not imply more than the validated or verified method can support. |
| Are deviations and data-integrity requirements controlled? | Regulated release testing requires audit-ready documentation, traceability, and deviation handling. |
Technical Resources and Publications
These examples cite Triclinic source documents, regulatory guidances, or literature relevant to this cGMP service. Download buttons are positioned at the bottom-left of each example.
ICH Q2(R2) Validation of Analytical Procedures and ICH Q14 Analytical Procedure Development
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: These harmonized guidances describe validation and development principles for analytical procedures used to assess drug-substance and drug-product quality. They anchor expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence in cGMP work.
Related cGMP services
NMR
Use cGMP NMR for identity, purity, qNMR, reference-material verification, method development, validation, and release testing.
View serviceXRPD
Use cGMP XRPD for solid-form identification, polymorph or phase quantitation, crystallinity, method validation, release, and stability support.
View serviceParticle Size Analysis
Develop, validate, verify, and transfer wet or dry particle-size methods for release specifications and quality decisions.
View serviceThermal Analysis (TGA/DSC)
Use cGMP DSC and TGA to evaluate melting, desolvation, dehydration, glass transitions, degradation, and thermal material control.
View serviceRaman / FTIR
Use cGMP Raman and FTIR for raw-material ID, solid-form differentiation, mapping, contaminant ID, and validated spectroscopic methods.
View serviceMorphology
Use cGMP microscopy and particle morphology evidence for identification, particle shape, foreign-material work, and regulated investigations.
View serviceCommon questions
Common questionsWhen should release testing be performed under cGMP?
Use cGMP controls when results will support batch disposition, stability, a Certificate of Analysis, regulatory documentation, or a quality investigation rather than exploratory screening only.
Can release testing begin before a method is validated, verified, or transferred?
Not for a release decision unless the procedure has the method status and documented suitability required for its intended use. Triclinic can assess readiness and perform development, validation, verification, or transfer work before controlled release execution.
How much sample is needed for release testing?
Requirements depend on the test panel, matrix, replicate design, standards, destructive tests, retain needs, and retesting policy. Confirm the exact amount before shipment.
What makes a cGMP release result defensible?
Defensible results require an appropriate method status, representative samples, traceable standards, system suitability, controlled execution, complete calculations, analyst and quality review, deviation handling, and clear reporting of limitations.
How are OOS or atypical results handled?
Unexpected results are documented and assessed under the applicable quality procedure. The assessment may review laboratory execution, instruments, standards, calculations, sample history, matrix behavior, method suitability, and the need for a broader investigation.
Can Triclinic support solid-state release specifications?
Yes. Release programs may use X-ray powder diffraction, Raman or Fourier-transform infrared spectroscopy, thermal analysis, particle-size analysis, microscopy, or other methods when the procedure is suitable for the matrix and specification.
Can Triclinic support recurring release-testing programs?
Yes. Recurring programs should define forecasted volume, sample and standard supply, method ownership, specifications, turnaround expectations, quality agreements, OOS responsibilities, reporting, retains, and change control.
Who makes the final batch-disposition decision?
Triclinic provides the agreed analytical results, reports, and scientific interpretation. The client’s authorized quality unit makes the final batch-disposition decision unless an applicable quality agreement defines another authorized process.
Discuss cGMP testing requirements
Send the sample type, intended use of the data, method or monograph if available, specification, matrix, timeline, and whether the work is exploratory, cGMP, validation, transfer, stability, release, or investigation support.